6 With 11 brands already on the market and more than 40 more in the pipeline, 7 these medications will target the nearly 100 million Americans categorized as obese
This leads to decreased hunger, slower digestion, and better glucose control
GLP-1 is one of the main hormone pathways involved in appetite control
GLP-1 drops have broadened the options for people seeking out medications for weight loss, and are especially appealing for those who want a needle-free alternative
Early Phase Possible appetite or fullness changes Digestive adjustment Possible nausea or bloating Response varies by dose and individual tolerance First Few Weeks Some patients may notice appetite changes Eating patterns may begin to shift Energy and blood sugar response may vary Digestive adjustment may continue Provider follow-up helps guide next steps Ongoing Early Treatment Some patients may begin noticing weight-related changes Portion sizes may change Appetite patterns may continue adjusting Side effects may improve or require provider guidance Progress depends on the individual treatment plan Continued Provider Monitoring Provider reviews response and tolerance Weight-related progress may vary Appetite patterns may continue changing Lifestyle habits may support progress Dose or care plan may be adjusted if appropriate Longer-Term Follow-Up Ongoing progress varies by patient Provider may review labs, tolerance, and treatment response Lifestyle habits may support long-term weight management Treatment may continue, change, or stop based on clinical review What Affects How Fast You See Results
.webp)
That could prevent somebody from utilizing dialysis, she said
